Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

Perez-Vilar S, Weibel D, Sturkenboom M, Black S, Maure C, Castro JL, Bravo-Alcántara P, Dodd CN, Romio SA, de Ridder M, Nakato S, Molina-León HF, Elango V, Zuber PLF; WHO Global Vaccine Safety-Multi Country Collaboration.

Vaccine. 2018 Jan 8;36(3):347-354. doi: 10.1016/j.vaccine.2017.05.012. Epub 2017 May 27.

2.

Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study.

Simpson CR, Lone NI, Kavanagh K, Robertson C, McMenamin J, von Wissmann B, Vasileiou E, Butler C, Ritchie LD, Gunson R, Schwarze J, Sheikh A.

BMJ Open. 2017 Feb 28;7(2):e014200. doi: 10.1136/bmjopen-2016-014200.

3.

The use of relative incidence ratios in self-controlled case series studies: an overview.

Hawken S, Potter BK, Little J, Benchimol EI, Mahmud S, Ducharme R, Wilson K.

BMC Med Res Methodol. 2016 Sep 23;16(1):126.

4.

Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish Infants.

Leino T, Ollgren J, Strömberg N, Elonsalo U.

PLoS One. 2016 Mar 7;11(3):e0144812. doi: 10.1371/journal.pone.0144812. eCollection 2016.

5.

Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England.

Stowe J, Andrews N, Kosky C, Dennis G, Eriksson S, Hall A, Leschziner G, Reading P, Shneerson JM, Donegan K, Miller E.

Sleep. 2016 May 1;39(5):1051-7. doi: 10.5665/sleep.5752.

6.

A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron SD, Cameron DW.

PLoS One. 2015 Nov 11;10(11):e0142205. doi: 10.1371/journal.pone.0142205. eCollection 2015.

7.

Methodological challenges in measuring vaccine effectiveness using population cohorts in low resource settings.

King C, Beard J, Crampin AC, Costello A, Mwansambo C, Cunliffe NA, Heyderman RS, French N, Bar-Zeev N; VacSurv Consortium.

Vaccine. 2015 Sep 11;33(38):4748-55. doi: 10.1016/j.vaccine.2015.07.062. Epub 2015 Jul 30. Review.

8.

Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines.

Requena G, Logie J, Martin E, Boudiaf N, González González R, Huerta C, Alvarez A, Webb D, Bate A, García Rodríguez LA, Reynolds R, Schlienger R, Gardarsdottir H, de Groot M, Klungel OH, de Abajo F, Douglas IJ.

Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:79-87. doi: 10.1002/pds.3822. Epub 2015 Jun 26.

9.

Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance.

Layton D, Shakir SA.

Drug Saf. 2015 Feb;38(2):153-63. doi: 10.1007/s40264-014-0260-x. Review.

10.

The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.

Lopalco PL, DeStefano F.

Vaccine. 2015 Mar 24;33(13):1541-8. doi: 10.1016/j.vaccine.2014.10.047. Epub 2014 Nov 4. Review.

11.

Childhood intussusception: a literature review.

Jiang J, Jiang B, Parashar U, Nguyen T, Bines J, Patel MM.

PLoS One. 2013 Jul 22;8(7):e68482. doi: 10.1371/journal.pone.0068482. Print 2013. Review.

12.

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation.

Live Dengue Vaccines Technical Consultation Reporting Group, Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, Hombach J, Farrar J.

Vaccine. 2013 May 28;31(23):2603-9. doi: 10.1016/j.vaccine.2013.03.038. Epub 2013 Apr 6.

13.

Case-only designs in pharmacoepidemiology: a systematic review.

Nordmann S, Biard L, Ravaud P, Esposito-Farèse M, Tubach F.

PLoS One. 2012;7(11):e49444. doi: 10.1371/journal.pone.0049444. Epub 2012 Nov 16. Review.

14.

Pharmacoepidemiology.

Evans SJ.

Br J Clin Pharmacol. 2012 Jun;73(6):973-8. doi: 10.1111/j.1365-2125.2012.04248.x.

15.

Future cases as present controls to adjust for exposure trend bias in case-only studies.

Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, Wellenius GA.

Epidemiology. 2011 Jul;22(4):568-74. doi: 10.1097/EDE.0b013e31821d09cd.

16.

Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Greene SK, Kulldorff M, Lewis EM, Li R, Yin R, Weintraub ES, Fireman BH, Lieu TA, Nordin JD, Glanz JM, Baxter R, Jacobsen SJ, Broder KR, Lee GM.

Am J Epidemiol. 2010 Jan 15;171(2):177-88. doi: 10.1093/aje/kwp345. Epub 2009 Dec 4.

17.

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.

Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY.

Osteoporos Int. 2010 Jul;21(7):1181-7. doi: 10.1007/s00198-009-1050-7. Epub 2009 Oct 6.

18.
19.

Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.

Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L.

Br J Clin Pharmacol. 2008 Nov;66(5):689-94. doi: 10.1111/j.1365-2125.2008.03273.x. Epub 2008 Jul 31.

Supplemental Content

Support Center